Release date: 6 October 2017
Promoter – Financial Intermediary
Financing of Indivumed's Capex / R&D costs, mostly related to the development of their cancer database (biobank expansion and artificial intelligence tool combined). The activities included in the project will help: (1) expand the clinical network and diversification of patient subgroups and tumors; (2) enhance the biological characterisation and classification of tissues with multiple clinical data points; (3) establish a bioinformatics and artificial intelligence solution to understand phenotypic and clinical data.
The proposed transaction will help the promoter to increase and accelerate the company's investments in strategic and innovative R&D activities.
- Services - Professional, scientific and technical activities
Proposed EIB finance (Approximate amount)
EUR 40 million
Total cost (Approximate amount)
EUR 95 million
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Signed - 8/01/2018
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).